US20180296636A1

US20180296636A1 - Btnl9 and ermap as novel inhibitors of the immune system for immunotherapies

Info

Publication number: US20180296636A1
Application number: US15/525,092
Authority: US
Inventors: Xingxing Zang; Kaya Ghosh
Original assignee: Albert Einstein College of Medicine
Current assignee: Albert Einstein College of Medicine
Priority date: 2014-11-25
Filing date: 2015-11-12
Publication date: 2018-10-18
Also published as: EP3223849A1; CN106999584A; WO2016085662A1; US20200338161A1; EP3223849A4

Abstract

Provided are methods of treating a tumor in a subject with a BTNL9-binding antibody. Also provided are methods of treating a tumor in a subject with an ERMAP-binding antibody. A fusion protein comprising a BTNL9 or ERMAP and related compositions and encoding nucleic acids are also provided.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. Provisional Application No. 62/084,124, filed Nov. 25, 2014, the contents of which are hereby incorporated by reference.

STATEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under grant numbers DK083076 and DK007218 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

The disclosures of all publications, patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.
Cancers, autoimmune diseases, infectious diseases, and transplantation rejection are serious public health problems in the US and other countries. The immune system, particularly T cells, plays critical roles in these diseases.
The B7 ligand family and CD28 receptor family control T cell activation and function. Both CTLA-4 and PD-1 are members of the CD28 family, and an antibody against CTLA-4 (Yervoy from Bristol-Myers Squibb) and an antibody against PD-1 (Keytruda, Merck) were approved by the FDA as new drugs for melanoma in 2011 and 2014, respectively. PD-L1 is a member of the B7 family, and antibodies to PD-L1 are in clinical trials with cancer patients. In additional, CTLA-4-Ig (Orencia) was approved by the FDA as a new drug for adult rheumatoid arthritis.
The existing technologies work by blockade of the B7/CD28 family members. The butyrophilin family is related to the B7 family, but their expression and functions in the immune system are largely unknown.
The present invention provides addresses the need for improved therapies and therapeutics based on targeting BTNL9 or ERMAP.

SUMMARY OF THE INVENTION

A method of treating a tumor in a subject comprising administering to the subject an amount of a BTNL9-binding antibody, or BTNL9-binding fragment thereof, sufficient to inhibit a BTNL9 and treat the tumor.
A method of treating a tumor in a subject comprising administering to the subject an amount of a ERMAP-binding antibody, or ERMAP-binding fragment thereof, sufficient to inhibit a ERMAP and treat the tumor.
A method of treating a tumor in a subject comprising administering to the subject an amount of a BTNL2-binding antibody, or BTNL2-binding fragment thereof, sufficient to inhibit a BTNL2 and treat the tumor.
A method of treating an autoimmune disease in a subject comprising administering to the subject an amount of an isolated, plasma-soluble BTNL9 to treat the autoimmune disease.
A method of treating an autoimmune disease in a subject comprising administering to the subject an amount of an isolated, plasma-soluble ERMAP to treat the autoimmune disease.
A method of treating an autoimmune disease in a subject comprising administering to the subject an amount of an isolated, plasma-soluble BTNL2 to treat the autoimmune disease.
An isolated, recombinant fusion polypeptide comprising a BTNL9 fused to an immunoglobulin polypeptide.
An isolated, recombinant fusion polypeptide comprising an ERMAP fused to an immunoglobulin polypeptide.
An isolated, recombinant fusion polypeptide comprising a BTNL2 fused to an immunoglobulin polypeptide.
An isolated chimeric nucleic acid encoding an isolated recombinant fusion polypeptide as described herein.
A composition comprising an isolated recombinant fusion polypeptide as described herein and a carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-1B. mRNA transcripts of BTN and BTNL family members in mouse tissues and antigen-presenting cells relative to the reference gene OAZ1. (A) Transcripts in naïve mouse tissues. Transcripts of BTN family members (upper panel) show that BTN transcripts are most abundant in mammary tissue. Transcripts of BTNL family members with intracellular SPRY domains (center panel) and of those without intracellular SPRY domains (bottom panel) are highest in the small and large intestines. Transcripts are also generally detectable in other tissues, particularly the primary lymphoid organs; MOG transcripts are highest in brain tissue. SP, spleen; LN, pooled inguinal and brachial lymph nodes; TH, thymus; BM, bone marrow; MLN, mesenteric lymph node; BR, brain; LU, lung; HE, heart; LI, liver; ST, stomach; SM, small intestine; LG, large intestine; PA, pancreas; KI, kidney; BL, bladder; SV, seminal vesicles; PR, prostate; EP, epididymis; TE, testis; FT, Fallopian tube; VA, vagina; UT, uterus; OV, ovary; MA, mammary gland. (B) Transcripts in resting and activated antigen-presenting cells (APCs). Transcripts for most genes are detectable in all three professional APCs, are in most cases lower in macrophages compared to dendritic cells and B cells, and are generally not strongly up- or down-regulated upon activation by LPS or PMA+ionomycin.

FIG. 2A-2C. Most recombinant BTN and BTNL family members inhibit the function of anti-CD3-activated primary mouse T cells. T cells were isolated from mouse spleen and lymph nodes by magnetic cell separation and activated with 2.5 μg/mL plate-bound anti-CD3 in the presence of 4 μg/mL plate-bound BTN- and BTNL-human Ig recombinant fusion proteins. (A) All BTN and BTNL fusion proteins, with the exception of ERMAP and MOG, reduce the metabolic activity of CD4+ T cells by 3 days post-activation. Human Ig (hIg), B7x-hIg, and B7.2-hIg fusion proteins are included as baseline, negative, and positive controls for activation, respectively. (B) BTN and BTNL fusion proteins reduce proliferation of activated CD4+ and CD8+ T cells. CD90.2+ T-cells were pulsed with CFSE prior to activation for 4 days, and stained with fluorescence-labeled antibodies to CD4 and CD8. CD4+ T cells (upper panel) showed reduced proliferation in the presence of BTN, BTN2, BTNL1, BTNL2 (full- and partial length), BTNL4, BTNL6, BTNL9, and ERMAP, and CD8+ T cells (panel) showed reduced proliferation in the presence of BTN, BTN2, BTNL1, BTNL2 (full- and partial-length), BTNL4, BTNL6, and BTNL9. The division indices, i.e., average number of divisions (closed bars), and percent divided (open bars) of CD4+ and CD8+ T cells are shown to the right of the histograms. (C) Secretion of the cytokines IFN-γ, IL-2, TNF-α, and IL-17A by CD4+ T cells 2 days post-activation is reduced in the presence of BTN and BTNL fusion proteins compared to baseline (hIg).

FIG. 3A-3B. CD4+ (A) and CD8+ (B) T cells activated for 3 days express a receptor for BTN and BTNL proteins. Total lymph node cells were activated by plate-bound 2.5 μg/mL anti-CD3 and incubated with biotinylated BTN-, BTNL-hIg, or hIg-fusion protein, stained with fluorescence-labeled antibodies to CD4 and CD8, and evaluated for fusion protein binding with fluorescence-labeled streptavidin. Both activated T cell subsets express a receptor for all BTN and BTNL family members, with the exception of MOG, which is consistent with functional data.

FIG. 4. The IgV1 domain of human BTNL2 bound human CD8 T cells, human B cells, and human NK cells. BTNL2-IgV1-Ig protein (open histograms) and control Ig (shaded histograms) are shown in FACS assays.

FIG. 5. The IgV1 domain of human BTNL9 bound human CD8 T cells, human B cells, and human NK cells. BTNL9-IgV1-Ig protein (open histograms) and control Ig (shaded histograms) are shown in FACS assays.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides the first disclosure that butyrophilin-like 9 (BTNL9) and erythroblast membrane-associated protein (ERMAP), two members of the butyrophilin family, inhibit T cell functions. A short form of BTNL2 was also strongly inhibitory. In particular, evidence that recombinant proteins of BTNL9 and ERMAP inhibit cell proliferation and cytokine production of T cells and that activated T cells have receptors for BTNL9 and ERMAP is provided. Since BTNL9 and ERMAP are expressed by immune cells or other cells. Applications of targeting these two molecules to enhance immunity (e.g. cancer immunotherapy) or decrease immunity (e.g. therapy of autoimmune diseases) are encompassed. Also, applications of using BTNL2, especially the short or “partial” form are encompassed.
BTNL9 is an inhibitor of the immune system. Therefore blockade of BTNL9-mediated immune suppression with blockers (e.g. monoclonal antibodies to BTNL9) can be used for treatment of human cancers and infectious diseases, while enhancement of BTNL9-mediated immune suppression with soluble proteins (e.g. BTNL9-Ig) can be used for treatment of autoimmune diseases and transplantation.
ERMAP is an inhibitor of the immune system. Therefore blockade of ERMAP-mediated immune suppression with blockers (e.g. monoclonal antibodies to ERMAP) can be used for treatment of human cancers and infectious diseases, and enhancement of ERMAP-mediated immune suppression with soluble proteins (e.g. ERMAP-Ig) can be used for treatment of autoimmune diseases and transplantation.
A method of treating a tumor is provided in a subject comprising administering to the subject an amount of a BTNL9-binding antibody, or BTNL9-binding fragment thereof, sufficient to inhibit a BTNL9 and treat the tumor.
Also provided is a method of treating a tumor in a subject comprising administering to the subject an amount of a ERMAP-binding antibody, or ERMAP-binding fragment thereof, sufficient to inhibit a ERMAP and treat the tumor.
Also provided is a method of treating a tumor in a subject comprising administering to the subject an amount of a BTNL2-binding antibody, or BTNL2-binding fragment thereof, sufficient to inhibit a BTNL2 and treat the tumor.
In an embodiment, the BTNL9 is a human BTNL9. In an embodiment, the ERMAP is a human ERMAP. In an embodiment, the BTNL2 is a human BTNL2.
In an embodiment of the methods, the tumor is a tumor of a breast, lung, thyroid, melanoma, pancreas, ovary, liver, bladder, colon, prostate, kidney, esophagus, or is a hematological tumor, or wherein the tumor is a lymphoid organ tumor.
In an embodiment of the methods, the antibody is administered as an adjunct to an additional anti-cancer therapy for the tumor.
In an embodiment of the methods, the amount of a BTNL9-binding antibody is administered. In an embodiment of the methods, the BTNL9-binding antibody binds an IgV1 domain of human BTNL9.
In an embodiment of the methods, the amount of a ERMAP-binding antibody is administered.
In an embodiment of the methods, the amount of a BTNL2-binding antibody is administered. In an embodiment of the methods, the BTNL2-binding antibody binds an IgV1 domain of human BTNL2.
In an embodiment of the methods, the fragment of the antibody is administered.
In an embodiment of the methods, the antibody is a monoclonal antibody.
In an embodiment of the invention, the BTNL9 is human BTNL9. In an embodiment human BTNL9 protein has the sequence:

(SEQ ID NO: 1)

MVDLSVSPDSLKPVSLTSSLVFLMHLLLLQPGEPSSEVKVLGPEYPIL

ALVGEEVEFPCHLWPQLDAQQMEIRWFRSQTFNVVHLYQEQQELPGRQ

MPAFRNRTKLVKDDIAYGSVVLQLHSIIPSDKGTYGCRFHSDNFSGEA

LWELEVAGLGSDPHLSLEGFKEGGIQLRLRSSGWYPKPKVQWRDHQGQ

CLPPEFEAIVWDAQDLFSLETSVVVRAGALSNVSVSIQNLLLSQKKEL

VVQIADVFVPGASAWKSAFVATLPLLLVLAALALGVLRKQRRSREKLR

KQAEKRQEKLTAELEKLQTELDWRRAEGQAEWRAAQKYAVDVTLDPAS

AHPSLEVSEDGKSVSSRGAPPGPAPGHPQRFSEQTCALSLERFSAGRH

YWEVHVGRRSRWFLGACLAAVPRAGPARLSPAAGYWVLGLWNGCEYFV

LAPHRVALTLRVPPRRLGVFLDYEAGELSFFNVSDGSHIFTFHDTFSG

ALCAYFRPRAHDGGEHPDPLTICPLPVRGTGVPEENDSDTWLQPYEPA

DPALDWW.

In an embodiment of the invention, the ERMAP is human ERMAP. In an embodiment human ERMAP protein has the sequence:

(SEQ ID NO: 2)

MEMASSAGSWLSGCLIPLVFLRLSVHVSGHAGDAGKFHVALLGGTAEL

LCPLSLWPGTVPKEVRWLRSPFPQRSQAVHIFRDGKDQDEDLMPEYKG

RTVLVRDAQEGSVTLQILDVRLEDQGSYRCLIQVGNLSKEDTVILQVA

APSVGSLSPSAVALAVILPVLVLLIMVCLCLIWKQRRAKEKLLYEHVT

EVDNLLSDHAKEKGKLHKAVKKLRSELKLKRAAANSGWRRARLHFVAV

TLDPDTAHPKLILSEDQRCVRLGDRRQPVPDNPQRFDFVVSILGSEYF

TTGCHYWEVYVGDKTKWILGVCSESVSRKGKVTASPANGHWLLRQSRG

NEYEALTSPQTSFRLKEPPRCVGIFLDYEAGVISFYNVTNKSHIFTFT

HNFSGPLRPFFEPCLHDGGKNTAPLVICSELHKSEESIVPRPEGKGHA

NGDVSLKVNSSLLPPKAPELKDIILSLPPDLGPALQELKAPSF.

In an embodiment of the invention, the BTNL2 is human BTNL2. In an embodiment human ERMAP protein has the sequence:

(SEQ ID NO: 3)

MVDCPRYSLSGVAASFLFVLLTIKHPDDFRVVGPNLPILAKVGEDALL

TCQLLPKRTTAHMEVRWYRSDPAMPVIMYRDGAVVTGLPMEGYGGRAE

WMEDSTEEGSVALKIRQVQPSDDGQYWCRFQEGDYWRETSVLLQVAAL

GSSPNIHVEGLGEGEVQLVCTSRGWFPEPEVHWEGIWGEKLMSFSENH

VPGEDGLFYVEDTLMVRNDSVETISCFIYSHGLRETQEATIALSERLQ

TELVSVSVIGHSQPSPVQVGENIELTCHLSPQTDAQNLEVRWLRSRYY

PAVHVYANGTHVAGEQMVEYKGRTSLVTDAIHEGKLTLQIHNARTSDE

GQYRCLFGKDGVYQEARVDVQVTAVGSTPRITREVLKDGGMQLRCTSD

GWFPRPHVQWRDRDGKTMPSFSEAFQQGSQELFQVETLLLVTNGSMVN

VTCSISLPLGQEKTARFPLSDSKI.

In an embodiment of the invention, the short form of BTNL2 is a short form of human BTNL2. In an embodiment the short form of human BTNL2 has the sequence:

(SEQ ID NO: 4)

MVDCPRYSLSGVAASFLFVLLTIKHPDDFRVVGPNLPILAKVGEDALL

TCQLLPKRTTAHMEVRWYRSDPAMPVIMYRDGAVVTGLPMEGYGGRAE

WMEDSTEEGSVALKIRQVQPSDDGQYWCRFQEGDYWRETSVLLQVAAL

GSSPNIHVEGLGEGEVQLVCTSRGWFPEPEVHWEGIWGEKLMSFSENH

VPGEDGLFYVEDTLMVRNDSVETISCFIYSHGLRETQEATIALSERLQ

TELVSVSVIGHSQPSPVQVG.

Protein sequence of the IgV1 domain of human BTNL2:

(SEQ ID NO: 5)

KQSEDFRVIGPAHPILAGVGEDALLTCQLLPKRTTMHVEVRWYRSEPS

TPVFVHRDGVEVTEMQMEEYRGWVEWIENGIAKGNVALKIHNIQPSDN

GQYWCHFQDGNYCGETSLLLKVAGLGSAPSIHM.

Protein sequence of the IgV1 domain of human BTNL9:

(SEQ ID NO: 6)

EVKVLGPEYPILALVGEEVEFPCHLWPQLDAQQMEIRWFRSQTFNVVH

LYQEQQELPGRQMPAFRNRTKLVKDDIAYGSVVLQLHSIIPSDKGTYG

CRFHSDNFSGEALWELEVAGLGSDPHLS.

In an embodiment of the methods, the tumor is a tumor of a breast, lung, thyroid, melanoma, pancreas, ovary, liver, bladder, colon, prostate, kidney, esophagus, or is a hematological tumor. In an embodiment of the methods, the tumor is a hematological tumor and is a leukemia or a lymphoma. In an embodiment of the methods, the tumor is a tumor of the breast and is a triple negative breast cancer. In an embodiment of the methods, the tumor is a tumor of a lymphoid organ.
Also provided is an isolated fusion protein comprising a soluble portion of an BTNL9 and an Fc portion of an immunoglobulin G.
Also provided is an isolated fusion protein comprising a soluble portion of an ERMAP and an Fc portion of an immunoglobulin G.
An isolated chimeric nucleic acid encoding an isolated fusion protein as described herein is provided.
A composition comprising the isolated fusion protein as described herein and a carrier is provided.
In an embodiment, the composition is a pharmaceutical composition, and the carrier is a pharmaceutical carrier.
Also provided is a method of treating an autoimmune disease in a subject comprising administering to the subject an amount of an isolated, plasma-soluble BTNL9 to treat the autoimmune disease.
Also provided is a method of treating an autoimmune disease in a subject comprising administering to the subject an amount of an isolated, plasma-soluble ERMAP to treat the autoimmune disease.
Also provided is a method of treating an autoimmune disease in a subject comprising administering to the subject an amount of an isolated, plasma-soluble BTNL2 to treat the autoimmune disease.
In an embodiment, the BTNL-2 comprises SEQ ID NO:4 but does not comprise SEQ ID NO:3.
In an embodiment, the plasma-soluble BTNL9, or the plasma-soluble ERMAP, respectively, comprises an BTNL9 fused to an immunoglobulin polypeptide, or an ERMAP fused to an immunoglobulin polypeptide, respectively.
In an embodiment, the plasma-soluble BTNL2 comprises an BTNL2 fused to an immunoglobulin polypeptide.
In an embodiment, the immunoglobulin polypeptide comprises an Fc portion of an immunoglobulin G.
Also provided is an isolated, recombinant fusion polypeptide comprising a BTNL9 fused to an immunoglobulin polypeptide. Also provided is an isolated, recombinant fusion polypeptide comprising an IgV1 domain of human BTNL9 fused to an immunoglobulin polypeptide. In an embodiment, the IgV1 domain of human BTNL9 comprises SEQ ID NO:6.
Also provided is an isolated, recombinant fusion polypeptide comprising an ERMAP fused to an immunoglobulin polypeptide.
Also provided is an isolated, recombinant fusion polypeptide comprising a BTNL2 fused to an immunoglobulin polypeptide. In an embodiment, the BTNL-2 comprises SEQ ID NO:4 but does not comprise SEQ ID NO:3. Also provided is an isolated, recombinant fusion polypeptide comprising an IgV1 domain of human BTNL2 fused to an immunoglobulin polypeptide. In an embodiment, the IgV1 domain of human BTNL2 comprises SEQ ID NO:5.
Also provided is an isolated chimeric nucleic acid encoding an isolated recombinant fusion polypeptide as described herein.
Also provided is a composition comprising the isolated recombinant fusion polypeptide as described herein and a carrier. In an embodiment, the compositions is a pharmaceutical composition, and comprises a pharmaceutical carrier.
The term “ERMAP-Ig” fusion protein as used herein means a fusion protein constructed of a portion of an immunoglobulin and an active portion of a ERMAP, or proteins having an identical sequence thereto. In a preferred embodiment, the active portion of a ERMAP is a soluble portion of ERMAP. In an embodiment, the ERMAP has the sequence of a human ERMAP. In an embodiment, the portion of an immunoglobulin is a portion of an IgG or an IgM. In an embodiment, it as a portion of an IgG. The IgG portion of the fusion protein can be, e.g., any of an IgG1, IgG2, IgG2a, IgG2b, IgG3 or IgG4 or a portion thereof. In an embodiment, the portion is an Fc region. In an embodiment the fusion protein comprises a sequence identical to an Fc portion of a human IgG1, human IgG2, human IgG2a, human IgG2b, human IgG3 or human IgG4. In an embodiment the fusion protein comprises a sequence identical to an Fc portion of a human IgG1. The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain, including native sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. The C-terminal lysine of the Fc region may be removed, for example, by recombinantly engineering the nucleic acid encoding the fusion protein.
The term “BTNL9-Ig” fusion protein as used herein means a fusion protein constructed of a portion of an immunoglobulin and an active portion of a BTNL9, or proteins having an identical sequence thereto. In an embodiment, the active portion of a BTNL9 is a soluble portion of BTNL9. In an embodiment, the BTNL9 has the sequence of a human BTNL9.
The term “BTNL2-Ig” fusion protein as used herein means a fusion protein constructed of a portion of an immunoglobulin and an active portion of a BTNL2, or proteins having an identical sequence thereto. In an embodiment, the active portion of a BTNL2 is a soluble portion of BTNL2. In an embodiment, the BTNL2 has the sequence of a human BTNL2. In an embodiment, the BTNL-2 comprises SEQ ID NO:4 but does not comprise SEQ ID NO:3.
In an embodiment, the portion of an immunoglobulin of the fusion proteins is a portion of an IgG or an IgM. In an embodiment, it as a portion of an IgG. The IgG portion of the fusion protein can be, e.g., any of an IgG1, IgG2, IgG2a, IgG2b, IgG3 or IgG4 or a portion thereof. In an embodiment, the portion is an Fc region. In an embodiment the fusion protein comprises a sequence identical to an Fc portion of a human IgG1, human IgG2, human IgG2a, human IgG2b, human IgG3 or human IgG4. In an embodiment the fusion protein comprises a sequence identical to an Fc portion of a human IgG1. The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain, including native sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. The C-terminal lysine of the Fc region may be removed, for example, by recombinantly engineering the nucleic acid encoding the fusion protein.
In an embodiment, the Fc portion of the Ig is used in the fusion proteins as described herein. The presence of the Fc domain markedly increases the plasma half-life of the attached protein, which prolongs therapeutic activity. In addition, the Fc domain also enables the fusion protein to interact with Fc-receptors. In an embodiment, the ERMAP-Ig comprises a ERMAP portion linked to an Fc domain. In an embodiment, the ERMAP portion is bound directly by a peptide bond to the Fc domain. In an embodiment, the ERMAP portion is linked to the Fc domain through a linker. In an embodiment, the BTNL9-Ig comprises a BTNL9 portion linked to an Fc domain. In an embodiment, the BTNL9 portion is bound directly by a peptide bond to the Fc domain. In an embodiment, the BTNL9 portion is linked to the Fc domain through a linker.
In an embodiment, the fusion protein (or fusion polypeptide) is linked via a peptide linker which permits flexibility. In an embodiment, the linker is rigid. In an embodiment the linker is cleavable. Non-limiting examples of flexible linkers within the scope of the invention are G_n, and GGGGS, and (GGGGS)_nwhere n=2, 3, 4 or 5 (SEQ ID NO:7). Non-limiting examples of rigid linkers within the scope of the invention are (EAAAK)_n(SEQ ID NO:8), (XP)_n. Non-limiting examples of cleavable linkers within the scope of the invention include disulfide links and protease cleavable linkers. In a preferred embodiment, the linker is a peptide linker.
In an embodiment, the Fc domain has the same sequence or 95% or greater sequence similarity with a human IgG1 Fc domain. In an embodiment, the Fc domain has the same sequence or 95% or greater sequence similarity with a human IgG2 Fc domain. In an embodiment, the Fc domain has the same sequence or 95% or greater sequence similarity with a human IgG3 Fc domain. In an embodiment, the Fc domain has the same sequence or 95% or greater sequence similarity with a human IgG4 Fc domain. In an embodiment, the Fc domain is not mutated. In an embodiment, the Fc domain is mutated at the CH2-CH3 domain interface to increase the affinity of IgG for FcRn at acidic but not neutral pH (Dall'Acqua et al, 2006; Yeung et al, 2009).
In an embodiment, the fusion protein described herein is recombinantly produced. In an embodiment, the fusion protein is produced in a eukaryotic expression system. In an embodiment, the fusion protein produced in the eukaryotic expression system comprises glycosylation at a residue on the Fc portion corresponding to Asn297.
In an embodiment, the fusion protein is a homodimer. In an embodiment, the fusion protein is monomeric. In an embodiment, the fusion protein is polymeric.
In an embodiment, a BTNL9-Ig is prepared by fusing the coding region of the extracellular domain of a BTNL9 having the same sequence as a human extracellular domain of a BTNL9 to a polypeptide having the same sequence as a human IgG1 Fc. Such can be made in any way known in the art, including by transfecting an appropriate cell type with a recombinant nucleic acid encoding the fusion protein. The BTNL2-Ig fusion protein can be made in an analogous matter, as can the other fusion proteins mentioned herein.
In an embodiment, a ERMAP-Ig is prepared by fusing the coding region of the extracellular domain of a ERMAP having the same sequence as a human extracellular domain of a ERMAP to a polypeptide having the same sequence as a human IgG1 Fc. Such can be made in any way known in the art, including by transfecting an appropriate cell type with a recombinant nucleic acid encoding the fusion protein.
In an embodiment, of all aspects of the invention described herein reciting a subject, the subject is a human
Cancers, including tumors, treatable by the invention include of the nasopharynx, pharynx, lung, bone, brain, sialaden, stomach, esophagus, testes, ovary, uterus, endometrium, liver, small intestine, appendix, colon, rectum, gall bladder, pancreas, kidney, urinary bladder, breast, cervix, vagina, vulva, prostate, thyroid, skin, or is a glioma. In an embodiment, the cancer treated is a metastatic melanoma.
This invention also provides a composition comprising a fusion protein as described herein. In an embodiment, the composition is a pharmaceutical composition. In an embodiment the composition or pharmaceutical composition comprising one or more of the fusion proteins described herein is substantially pure with regard to the fusion protein. A composition or pharmaceutical composition comprising one or more of the fusion proteins described herein is “substantially pure” with regard to the antibody or fragment when at least about 60 to 75% of a sample of the composition or pharmaceutical composition exhibits a single species of the fusion protein. A substantially pure composition or pharmaceutical composition comprising one or more of the fusion proteins described herein can comprise, in the portion thereof which is the fusion protein, 60%, 70%, 80% or 90% of the fusion protein of the single species, more usually about 95%, and preferably over 99%. Fusion protein purity or homogeneity may be tested by a number of means well known in the art, such as polyacrylamide gel electrophoresis or HPLC.
The invention also encompasses compositions comprising the described fusion proteins and a carrier. The carrier may comprise one or more pharmaceutically-acceptable carrier components. Such pharmaceutically-acceptable carrier components are widely known in the art.
In an embodiment, the subject being treated for cancer via a method herein is also treated with a chemotherapeutic agents, such as a cytotoxic agent. In an embodiment, the cytotoxic agent is doxorubicin. In an embodiment, the cytotoxic agent is a maytansinoid. In an embodiment, the cytotoxic agent an alkylating agent, an anti-metabolite, a plant alkaloid or terpenoid, or a cytotoxic antibiotic. In embodiments, the cytotoxic agent is cyclophosphamide, bleomycin, etoposide, platinum agent (cisplatin), fluorouracil, vincristine, methotrexate, taxol, epirubicin, leucovorin (folinic acid), or irinotecan.
Administration as used herein, unless otherwise stated, can be auricular, buccal, conjunctival, cutaneous, subcutaneous, endocervical, endosinusial, endotracheal, enteral, epidural, via hemodialysis, interstitial, intrabdominal, intraamniotic, intra-arterial, intra-articular, intrabiliary, intrabronchial, intrabursal, intracardiac, intracartilaginous, intracaudal, intracavernous, intracavitary, intracerebral, intracisternal, intracorneal, intracoronary, intradermal, intradiscal, intraductal, intraepidermal, intraesophagus, intragastric, intravaginal, intragingival, intraileal, intraluminal, intralesional, intralymphatic, intramedullary, intrameningeal, intramuscular, intraocular, intraovarian, intraepicardial, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrasinal, intraspinal, intrasynovial, intratendinous, intratesticular, intrathecal, intrathoracic, intratubular, intratumor, intratympanic, intrauterine, intravascular, intravenous, intraventricular, intravesical, intravitreal, laryngeal, nasal, nasogastric, ophthalmic, oral, oropharyngeal, parenteral, percutaneous, periarticular, peridural, rectal, inhalationally, retrobulbar, subarachnoid, subconjuctival, sublingual, submucosal, topically, transdermal, transmucosal, transplacental, transtracheal, ureteral, uretheral, and vaginal.
In an embodiment, the fusion protein of the invention is administered systemically in the methods described herein. In an embodiment, the fusion protein of the invention is administered locally in the methods described herein. In an embodiment, the fusion protein of the invention is administered directly to the tumor in the methods described herein, for example by injection or cannulation.
In an embodiment, the antibody or antibody fragment of the invention is administered systemically in the methods described herein. In an embodiment, the antibody or antibody fragment of the invention is administered locally in the methods described herein. In an embodiment, the antibody or antibody fragment of the invention is administered directly to the tumor in the methods described herein, for example by injection or cannulation.
In an embodiment, “determining” as used herein means experimentally determining.
All combinations of the various elements described herein are within the scope of the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
This invention will be better understood from the Experimental Details, which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims that follow thereafter.

EXPERIMENTAL DETAILS

The existing technologies for T-cell based immunotherapies regarding B7/CD28 family members work by blockade of the B7/CD28 family members. In contrast, the expression patterns and functions of BTNL9 and ERMAP, two members of the butyrophilin family, are different from CTLA-4 and PD-1 and their ligands, therefore, the BTNL9 pathway and the ERMAP pathway regulate the immune system at the different times and locations.

Example 1

mRNA expression of BTNL9, ERMAP and other members of the butyrophilin family in tissues and antigen-presenting cells: The butyrophilin family is related to the B7 family, but their expression and functions in the immune system are largely unknown. Using Real-Time RT-PCR, it was determined that BTNL9 and ERMAP, together with other family members, were widely expressed in many tissues and antigen-presenting cells (FIG. 1).

Example 2

BTNL9, ERMAP and some other members of the butyrophilin family inhibit T cell function: It was examined whether BTNL9, ERMAP and other members of the butyrophilin family were able to regulate T-cell function using a system modified from previous studies (PNAS, 110: 9879-9884, 2013). In this system, purified T cells were activated with plate-bound mAb to CD3 and the activation of T cells was determined on days 3 and T cell-derived cytokines were determined on day 2. It was determined that BTNL9 inhibited both CD4 and CD8 T cell proliferation and cytokine production, while ERMAP inhibited CD4, but not CD8 T cell proliferation (FIG. 2).

Example 3

Activated T cells have receptors for BTNL9, ERMAP and some other members of the butyrophilin family: Because BTNL9 and ERMAP inhibited T cell function, it was examined if activated T cells express receptors for these molecules. It was determined that BTNL9-Ig, BTNL9, ERMAP-Ig and other Ig fusion proteins of some members of the butyrophilin family bound to activated CD4 and CD8 T cells which were activated for three days (FIG. 3).

Example 4

The IgV1 domain of Human BTNL2 is the functional domain. As shown in FIG. 4, the IgV1 domain of human BTNL2 bound human CD8 T cells, human B cells, and human NK cells. BTNL2-IgV1-Ig protein (open histograms) and control Ig (shaded histograms) are shown in FACS assays. Sequence shown is SEQ ID NO:5.

Example 5

The IgV1 domain of Human BTNL9 is the functional domain. As shown in FIG. 5, the IgV1 domain of human BTNL9 bound human CD8 T cells, human B cells, and human NK cells. BTNL9-IgV1-Ig protein (open histograms) and control Ig (shaded histograms) are shown in FACS assays. Sequence shown is SEQ ID NO:6.

Claims

1. A method of treating a tumor in a subject comprising administering to the subject an amount of a BTNL9-binding antibody, or BTNL9-binding fragment thereof, sufficient to inhibit a BTNL9 and treat the tumor.

2. A method of treating a tumor in a subject comprising administering to the subject an amount of a ERMAP-binding antibody, or ERMAP-binding fragment thereof, sufficient to inhibit a ERMAP and treat the tumor.

3. A method of treating a tumor in a subject comprising administering to the subject an amount of a BTNL2-binding antibody, or BTNL2-binding fragment thereof, sufficient to inhibit a BTNL2 and treat the tumor.

4. The method of claim 1, wherein the BTNL9 is a human BTNL9.

5. The method of claim 2, wherein the ERMAP is a human ERMAP.

6. The method of claim 3, wherein the BTNL2 is a human BTNL2.

7. The method of claim 1, wherein the tumor is a tumor of a breast, lung, thyroid, melanoma, pancreas, ovary, liver, bladder, colon, prostate, kidney, esophagus, or is a hematological tumor, or wherein the tumor is a lymphoid organ tumor.

8. The method of claim 1, wherein the antibody is administered as an adjunct to an additional anti-cancer therapy for the tumor.

9. The method of claim 1, wherein the amount of a BTNL9-binding antibody is administered.

10. The method of claim 3, wherein the amount of a BTNL2-binding antibody is administered.

11. The method of claim 1, wherein the fragment of the antibody is administered.

12-15. (canceled)

16. The method of claim 15, wherein the BTNL-2 comprises SEQ ID NO:4 but does not comprise SEQ ID NO:3.

17. The method of claim 13, wherein the plasma-soluble BTNL9, or the plasma-soluble ERMAP, respectively, comprises an BTNL9 fused to an immunoglobulin polypeptide, or an ERMAP fused to an immunoglobulin polypeptide, respectively.

18. The method of claim 15, wherein the plasma-soluble BTNL2 comprises an BTNL2 fused to an immunoglobulin polypeptide.

19. The method of claim 17, wherein the immunoglobulin polypeptide comprises an Fc portion of an immunoglobulin G.

20-26. (canceled)